RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Frazier Life Sciences
F

Frazier Life Sciences portfolio

Frazier Life Sciences has 9 portfolio companies on record at Recent Funding, with 4 investments in the last 12 months.

Website: frazierls.com.
Type: Venture capital.
Portfolio on Recent Funding: 9.
Deals, last 12 months: 4.
Rounds led: 6 of 9.
Capital in their rounds: $1.27B.
Latest deal: RQ Bio · Jun 24, 2026.
About this page

It is a venture capital firm based in Palo Alto, US, founded in 2015. It led 6 of the 9 rounds it joined. Its most recent investment on record is RQ Bio's $115M Series A round in June 2026, which it led, alongside Forbion Capital Partners, EQT Life Sciences, Wellington Management and 4 others. By category, its portfolio leans toward Health and bio (9) and Logistics and mobility (1). It has co-invested with Longitude Capital, Nextech Invest and Janus Henderson Investors, most often Longitude Capital (3 rounds).

About Frazier Life Sciences

Firm type: Venture capital.
Headquarters: Palo Alto, US.
Founded: 2015.
Stages: Seed, Series A, Series B, Series C, Growth, Late Stage.
Sectors: Biotech, Healthtech, Medical Devices.
Leads rounds: Yes.
Portfolio companies: 179.
Exits: 24.
Rounds led: 8.

What Frazier Life Sciences invests in

Frazier Life Sciences recent investments

How Frazier Life Sciences invests

StageDealsCapital in rounds
Series B+ 6 67%$873M
Series A 3 33%$401.45M
YearDealsCapital in rounds
2024 4 44%$398M
2025 2 22%$475M
2026 3 33%$401.45M

Frazier Life Sciences portfolio companies

CompanyRound with Frazier Life SciencesTotal raisedLatest raise
RRQ Bio
Health and bio
Series A · $115M · lead$115MJun 24, 2026
Series A
IImmutrin
Health and bio
Series A · $86.45M · lead$86.45MMar 26, 2026
Series A
AAirNexis Therapeutics
Health and bio
Series A · $200M · lead$200MJan 9, 2026
Series A
AAspen Neuroscience
Health and bio
Series B+ · $115M · lead$339MNov 20, 2025
Series B+
TTubulis
Health and bio
Series B+ · $360M$573MOct 16, 2025
Series B+
335Pharma
Health and bio
Series B+ · leadundisclosedNov 26, 2024
Series B+
AAlpha-9 Oncology
Health and bio
Series B+ · $175M$175MOct 23, 2024
Series B+
LLassen Therapeutics
Health and bio
Series B+ · $85M · lead$116MJan 17, 2024
Series B+
AAngitia Bio
Health and bio
backer$130MFeb 12, 2026
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 9 rounds on Recent Funding that name Frazier Life Sciences. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Frazier Life Sciences, which is a subset of its real portfolio. API: /api/v1/investors/frazier-life-sciences (get a free API key). More: the most active VC firms and new venture capital funds.

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy